Tasly Pharmaceutical Group Co., Ltd (SHA:600535)

SHA:600535 Revenue

Tasly Pharmaceutical Group had revenue of 1.87B CNY in the quarter ending September 30, 2026, a decrease of -7.41%. This brings the company's total for the last twelve months to 8.00B, down -4.16% year-over-year. In the year 2025, Tasly Pharmaceutical Group had annual revenue of 8.24B, down -3.08%. That makes Tasly Pharmaceutical Group the 6,867th largest company in the world by revenue and 975th in China.

• Revenue (ttm): 8.00B
• Revenue Growth: -4.16%
• P/S Ratio: 2.69
• Revenue / Employee: 757.31K
• Employees: 10,563
• Market Cap: 21.50B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Industry 7.38B 89.7%
• Pharmaceutical Commercial 765.76M 9.3%
• Unallocated Other 77.78M 0.9%

By Geography

Chart

• China 8.16B 99.2%
• Overseas 61.73M 0.8%

Fiscal year ended Dec 31, 2025 See the full SHA:600535 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	8.24B	-261.66M	-3.08%
Dec 31, 2024	8.50B	-175.87M	-2.03%
Dec 31, 2023	8.67B	36.58M	0.42%
Dec 31, 2022	8.64B	685.47M	8.62%
Dec 31, 2021	7.95B	-5.62B	-41.43%

Data Source: S&P Global Market Intelligence Last updated: Oct 23, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 4, 2026

Data Sources Report a data error